论文部分内容阅读
目的:相对定量检测Runx2mRNA在甲状腺乳头状癌和腺瘤中的表达,并探讨其在甲状腺乳头状癌的发生发展及与钙化的意义。方法:相对定量real time RT-PCR检测14例甲状腺乳头状癌和14例甲状腺腺瘤中Runx2mRNA的表达。结果:癌组和腺瘤组的ΔCT值分别为2.395±0.302和5.028±1.179,两样本均数差别的t检验示两组之间差异有统计学意义(P<0.01);癌组和腺瘤组的2-ΔΔCT分别为7.826±5.004和1,两样本均数差别的t检验示两组之间差异有统计学意义(P<0.01)。癌组和腺瘤组内以钙化分组ΔCT结果示P>0.05,组间差异均无统计学意义。癌组按肿瘤大小<1cm和≥1cm分组,ΔCT值分别为2.629±0.300和2.212±0.124,P<0.05;2-ΔΔCT值分别为167.33±33.823和221.69±18.843,P<0.01。癌组和腺瘤组以及癌组内钙化分组TSH水平比较均P>0.05。结论:Runx2在甲状腺乳头状癌中的表达高,并与癌大小有关,在较大的癌中表达较高。Runx2与微钙化的关系,可能与甲状腺乳头状癌内钙化灶的产生及癌的发生发展有关,在其他的恶性肿瘤(如乳腺癌、前列腺癌、骨肉瘤)也有相关研究。
OBJECTIVE: To determine the expression of Runx2 mRNA in papillary thyroid carcinoma and adenoma with relative quantification, and to explore the significance of Runx2 mRNA expression in papillary thyroid carcinoma. Methods: Relative expression of Runx2 mRNA in 14 cases of thyroid papillary carcinoma and 14 cases of thyroid adenoma was detected by real time RT-PCR. Results: The ΔCT values of cancer group and adenoma group were 2.395 ± 0.302 and 5.028 ± 1.179, respectively. The t-test showed that there was significant difference between the two groups (P <0.01) The 2-ΔΔCT of the two groups were 7.826 ± 5.004 and 1, respectively. The t-test showed that there was a significant difference between the two groups (P <0.01). The results of ΔCT with calcification in cancer group and adenoma group showed P> 0.05, and there was no significant difference between the two groups. The cancer groups were grouped according to tumor size <1 cm and ≥1 cm. The ΔCT values were 2.629 ± 0.300 and 2.212 ± 0.124, respectively, P <0.05. The 2-ΔΔCT values were 167.33 ± 33.823 and 221.69 ± 18.843, respectively, P <0.01. The levels of TSH in the cancer group, the adenoma group and the calcification group in the cancer group were all P> 0.05. Conclusion: Runx2 is highly expressed in thyroid papillary carcinomas and is related to the size of the cancers and higher in the larger cancers. The relationship between Runx2 and microcalcification may be related to the occurrence of calcification and carcinogenesis in papillary thyroid carcinoma and other malignant tumors such as breast cancer, prostate cancer and osteosarcoma.